Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

RightEye buys rights to two eye movement tests to detect autism and Parkinson’s disease

Health technology firm RightEye has purchased the rights to two eye movement tests, which will enable doctors to identify autism and Parkinson’s disease.

The tests, which are based on extensive clinical studies, will allow doctors to detect early stages of autism in children 12 to 40 months old and Parkinson’s disease in patients of all ages.

The company has acquired GeoPref autism test, which was developed by University of California neurosciences department professor Dr Karen Pierce.

GeoPref autism test uses eye-tracking technology to compare the amount of time children spend looking at videos of people with the amount of time they spend looking at videos of geometric shapes.

As per the peer-reviewed research, the children with healthy brains will spend more time looking at the videos containing faces.

Pierce said: “In developing the GeoPref Autism Test, my goal was to make it easier, faster and more affordable to identify toddlers at risk for autism.”

Parkinson’s & Other Movement Disorders Test was developed by a team that includes VCU Parkinson's and Movemnet Disorders Center interim director Dr Mark Baron.

The test can accurately identify and evaluate patterns of eye movement, which are affected in patients with movement disorders. It takes nearly five minutes and provides accurate results compared to traditional diagnostic methods.

RightEye president Barbara Barclay said: “RightEye has consistently pioneered the use of eye-tracking technology to help solve some of health care’s greatest challenges.

“Acquiring these tests has implications that reach far beyond our business — as our eye movement technology platform will now enable parents, patients and providers to get the reliable and objective answers they need, when they need them, anywhere in the world, at a lower cost.”